(0) items in cart / view cart / checkout  
 
  Chemicals
  Company Profiles
  Country Analyses
  Electronics
  Food & Beverage
  In Vitro Diagnostics
  Medical Devices
  Pharmaceuticals & Biotechnology
 
Home > Pharmaceuticals & Biotechnology Ethical Pharmaceuticals >  Pharmaceutical Licensing Overview: Risk-Aversion Breeds Creativity as Externalization Intensifies

Pharmaceutical Licensing Overview: Risk-Aversion Breeds Creativity as Externalization Intensifies



 

Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending 2011 patent cliff. To fill pipeline voids with new products, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic.

Scope

  • Overview of Big Pharma's current and anticipated future reliance on externally sourced products
  • Overview of drivers and resistors of licensing deals and an assessment of key trends and factors that will shape the future make-up of licensing
  • Analysis of key product deals during 2008-09, analyzing trends for in-licensing, out-licensing and manufacturing/supply arrangements
  • Assessment of drug discovery and technology deals made by the top 10 pharmaceutical companies during 2008-09

Highlights

The number of in-licensing deals in 2009 increased by 12% over 2008, confirming that Big Pharma is actively seeking acquisitions and licensing agreements as a more cost-effective means of gaining access to novel products than carrying out extensive in-house R&D.

Although deals for drugs at the earliest stages of development accounted for almost 60% of all product in-licensing deals analyzed, Big Pharma greatly increased its focus on Phase II and III products in 2009 as it looks to offset the 2011 patent cliff by incorporating more advanced-stage products into its pipelines to enhance short/mid-term growth.

GlaxoSmithKline was by far the most active Big Pharma player. While many of its Big Pharma peers have participated in large M&A deals over the past 2 years, GlaxoSmithKline has thus far preferred to focus on incorporating externally acquired products into its pipeline.

Reasons to Purchase

  • Appreciate the drivers and resistors companies face when licensing products, and the resultant strategies some companies are employing
  • Identify suitable pharma partners to target when considering out-licensing your technologies and products
  • Understand the direction the constantly evolving pharmaceutical licensing landscape is moving in order to identify the best strategies to succeed

Contains 115 pages and 52 tables/figures



To order sections of this report, contact Client Services


     
   
Local PDF: $15200.00
Other Formats: Global PDF, DataPack
   
   
 
VPGMarketResearch.com © Copyright 2010. all rights reserved. Web Design by Spida Design  
  Close  X